SCHEMBL497724

SCHEMBL497724

NC(=O)c1cccc2cc3cc4ccccc4cc3cc12

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.96
ALDH1A1 P00352 5/20 0.96
GAA P10253 2/20 0.96
PDPK1 O15530 1/20 0.49
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 2/20 0.46
CTNNB1 P35222 1/20 0.46
HPGD P15428 3/20 0.45
HSD17B10 Q99714 2/20 0.45
TSHR P16473 1/20 0.45
PARP1 P09874 5/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
IKBKB O14920 1/20 0.43
ATM Q13315 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.42
NR4A1 P22736 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25192670 1.00 KDM4E (0.96) KDM4EALDH1A1GAAPDPK1KMT2A
Hydrochloric Acid SCHEMBL9566345 0.98 KDM4E (0.93) KDM4EALDH1A1GAAPDPK1KMT2A
Hydrochloric Acid SCHEMBL4811305 0.98 KDM4E (0.93) KDM4EALDH1A1GAAPDPK1KMT2A
SCHEMBL29100415 0.98 KDM4E (1.00) KDM4EALDH1A1GAAPDPK1KMT2A
SCHEMBL634215 0.98 KDM4E (1.00) KDM4EALDH1A1GAAPDPK1KMT2A
SCHEMBL29498815 0.98 KDM4E (1.00) KDM4EALDH1A1GAAPDPK1KMT2A
SCHEMBL30181949 0.98 KDM4E (1.00) KDM4EALDH1A1GAAPDPK1KMT2A
Sulfuric Acid SCHEMBL9566343 0.93 KDM4E (0.83) KDM4EALDH1A1GAAPDPK1KMT2A
SCHEMBL5746726 0.88 ALDH1A1 (0.75) KDM4EALDH1A1GAAPDPK1KMT2A
SCHEMBL5749892 0.88 ALDH1A1 (0.75) KDM4EALDH1A1GAAPDPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3003375-B1 METHOD OF APPLYING A COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH A REGIMEN OF ADMINISTERING IT HAFEZI FARHAD (CH) 2019-11-20 EP claimed
US-20160120979-A1 METHOD OF APPLYING A COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH A REGIMEN OF ADMINISTERING IT HAFEZI FARHAD (CH) 2016-05-05 US claimed
EP-3003375-A2 METHOD OF APPLYING A COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH A REGIMEN OF ADMINISTERING IT Hafezi, Farhad (CH) 2016-04-13 EP claimed
US-20150164922-A1 USE OF TETRACYCLINE COMPOSITIONS FOR WOUND TREATMENT AND SKIN RESTORATION FOAMIX PHARMACEUTICALS LTD. (IL) 2015-06-18 US claimed
US-20150056160-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. 2015-02-26 US claimed
WO-2014194435-A2 METHOD OF APPLYING A COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH A REGIMEN OF ADMINISTERING IT HAFEZI FARHAD (CH) 2014-12-11 WO claimed
US-20140228248-A1 METHODS AND COMPOSITIONS FOR DETECTING INFECTIONS BIOMED VALLEY DISCOVERIES, INC. (US) 2014-08-14 US claimed
WO-2013136192-A2 USE OF TETRACYCLINE COMPOSITIONS FOR WOUND TREATMENT AND SKIN RESTORATION FOAMIX LTD. (IL) 2013-09-19 WO claimed
WO-2013048952-A1 METHODS AND COMPOSITIONS FOR DETECTING INFECTIONS BIOMED VALLEY DISCOVERIES, INC. (US) 2013-04-04 WO claimed
WO-2008097851-A1 TETRACYCLINE COMPOSITIONS FOR TOPICAL ADMINISTRATION WARNER CHILCOTT COMPANY, INC. (US) 2008-08-14 WO claimed
WO-2005085863-A2 BIOMARKER: COMPOUND CORRELATIONS IN CANCER DIAGNOSIS AND THERAPY APPLIED GENOMICS, INC. (US) 2005-09-15 WO claimed
EP-1098641-A4 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA ST JUDE PHARMACEUTICALS INC (US) 2003-08-27 EP claimed
EP-1098641-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA Texas Pharmaceuticals, Inc. (US) 2001-05-16 EP claimed
WO-2000006143-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. (US) 2000-02-10 WO claimed
EP-0536515-A1 Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines AMERICAN CYANAMID COMPANY (US) 1993-04-14 EP claimed
EP-0535346-A1 9-amino-7-substituted-6-demethyl-6-deoxytetracyclines AMERICAN CYANAMID COMPANY (US) 1993-04-07 EP claimed
EP-0196376-B1 ARTICLE COATED WITH AN ANTIFOULING COMPOSITION FOR USE IN SEAWATER STARBRITE INTERNATIONAL N.V. (AN) 1989-12-13 EP claimed
US-4678512-A Marine coating compositions and method GRAMS RALPH R 1987-07-07 US claimed
EP-0196376-A1 Article coated with an antifouling composition for use in seawater STARBRITE INTERNATIONAL N.V. (AN) 1986-10-08 EP claimed
US-4552813-A Method of inhibiting the growth of marine life on surfaces in contact with seawater GRAMS RALPH R 1985-11-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160120979-A1 METHOD OF APPLYING A COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH A REGIMEN OF ADMINISTERING IT XPA, CD4, TK1 KDM4E 4556/4885ALDH1A1 2527/4885GAA 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.